Matus Studeny

3.6k citations
37 papers · 3.0k · 3 hit papers · h-index 17

Impact in

  • Genetics top 0.5%
    • Mesenchymal stem cell research
    • Virus-based gene therapy research
  • Oncology top 2%
    • Cancer Cells and Metastasis
    • CAR-T cell therapy research

Papers in

  • Oncology 22
    • CAR-T cell therapy research 6
    • Colorectal Cancer Treatments and Studies 6
    • Lung Cancer Research Studies 6
    • Cancer Immunotherapy and Biomarkers 4
    • Cancer Cells and Metastasis 4
  • Genetics 10
    • Mesenchymal stem cell research 8
Co-authors
Michael Andreeff (9 shared papers)Frank C. Marini (4 shared papers)Claudia Zompetta (3 shared papers)Jennifer L. Dembinski (8 shared papers)Richard E. Champlin (2 shared papers)Isaiah J. Fidler (1 shared paper)F. Marini (6 shared papers)B. Nebiyou Bekele (1 shared paper)
Journals
Journal of Clinical Oncology (11 papers)Annals of Oncology (8 papers)Journal of Thoracic Oncology (2 papers)European Journal of Cancer (2 papers)JNCI Journal of the National Cancer Institute (2 papers)
Partner nations
United StatesGermanyFrance

In The Last Decade

Matus Studeny

36 papers receiving 2.9k citations

Matus Studeny's Hit Papers

Human Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas 2005 · 868 citations
8680+8+16Years since publication250500750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2005 Cancer Research
  2. 2004 JNCI Journal of the National Cancer Institute
  3. 2002 PubMed

Peers

Matus Studeny
Comparison fields: 5 of 87
  • Genetics 1.5k
  • Oncology 1.2k
  • Cancer Research 401
  • Biotechnology 172
  • Genetics 497
Replace Erika L. Spaeth with:
Erika L. Spaeth United States
Joy Gumin United States
G Paradis United States
Ross Tubo United States
Ajeeta B. Dash United States
Venkata Lokesh Battula United States
Sandra A. Rempel United States
Robert W. Storms United States
Kent Claypool United States
Laurie A. Milner United States
Matus Studeny relative to Erika L. Spaeth United States Erika L. Spaeth's profile →
Citations per field
00.5×1.5×
Erika L. Spaeth · 1×
Citations per year

Countries citing papers authored by Matus Studeny

Since Specialization
Citations

This map shows the geographic impact of Matus Studeny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matus Studeny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matus Studeny more than expected).

Fields of papers citing papers by Matus Studeny

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matus Studeny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matus Studeny. The network helps show where Matus Studeny may publish in the future.

Co-authors

The 25 scholars most cited alongside Matus Studeny, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matus Studeny Line = papers co-authored together Matus Studeny links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Human Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
Cancer Research ·Akira Nakamizo, Frank C. Marini, Toshiyuki Amano, Asadullah Khan, Matus Studeny, Joy Gumin, Julianne Chen, Stephen J. Hentschel, Giacomo G. Vecil, Jennifer L. Dembinski, Michael Andreeff, Frederick F. Lang
Hit paper breakdown →		2005868
2
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.
PubMed ·Matus Studeny, Frank C. Marini, Richard E. Champlin, Claudia Zompetta, Isaiah J. Fidler, Michael Andreeff
Hit paper breakdown →		2002766
3
Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents
JNCI Journal of the National Cancer Institute ·Matus Studeny, F. Marini, Jennifer L. Dembinski, Claudia Zompetta, Maria da Graça Cabreira-Hansen, B. Nebiyou Bekele, Richard Champlin, M. Andreeff
Hit paper breakdown →		2004671
4
Mesenchymal Stem Cells in Cancer: Tumor-Associated Fibroblasts and Cell-Based Delivery Vehicles
International Journal of Hematology ·Brett M. Hall, Jennifer L. Dembinski, A. Kate Sasser, Matus Studeny, Michael Andreeff, Frank C. Marini
2007138
5
Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer
Cytotherapy ·Jennifer L. Dembinski, S. Wilson, Erika L. Spaeth, Matus Studeny, Claudia Zompetta, Ismael Samudio, Katherine F. Roby, Michael Andreeff, Frank C. Marini
201353
6
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
Annals of Oncology ·Eric Van Cutsem, Takayuki Yoshino, Heinz‐Josef Lenz, Sara Lonardi, Alfredo Falcone, M. Luisa Limon, Mark Saunders, Alberto Sobrero, Y.S. Park, Reyes Ferreiro, Yong Sang Hong, Jiří Tomášek, Hiroya Taniguchi, Fortunato Ciardiello, James D. Stoehr, Zohra Oum'Hamed, Soetkin Vlassak, Matus Studeny, Guillem Argilés
201849
7
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study
Investigational New Drugs ·Tim Eisen, Yaroslav Shparyk, Nicholas MacLeod, Robert J. Jones, G. Wallenstein, Graham Temple, Yasser Khder, Claudia Dallinger, Matus Studeny, Arsène‐Bienvenu Loembé, Igor Bondarenko
201348
8
Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells
Cancer Gene Therapy ·Jennifer L. Dembinski, Erika L. Spaeth, Juàn Fueyo, Candelaria Gomez‐Manzano, Matus Studeny, Michael Andreeff, F. Marini
200948
9
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas
Future Oncology ·Martin Wermke, Enriqueta Felip, Valentina Gambardella, Yasutoshi Kuboki, Daniel Morgensztern, Zohra Oum’ Hamed, Meiruo Liu, Matus Studeny, Taofeek K. Owonikoko
202237
10
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
Annals of Oncology ·Eric Van Cutsem, Hans Prenen, Geert D’Haens, Jaafar Bennouna, Alfredo Carrato, Michel Ducreux, Olivier Bouché, Alberto Sobrero, Luciano Latini, Harry Staines, Zohra Oum'Hamed, H Dressler, Matus Studeny, Jaume Capdevila
201535
11
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).
Journal of Clinical Oncology ·Martin Wermke, Enriqueta Felip, Yasutoshi Kuboki, Daniel Morgensztern, Cyrus Sayehli, Miguel F. Sanmamed, Edurne Arriola, Zohra Oum'Hamed, Eric Song, Matus Studeny, Valentina Gambardella
202333
12
Metabolism of a [18F]fluorine labeled progestin (21 -[18F]fluoro-16α -ethyl-19-norprogesterone) in humans: a clue for future investigations
Nuclear Medicine and Biology ·A. Verhagen, Matus Studeny, Gert Luurtsema, Gerben M. Visser, C.C.J. De Goeij, Mels Sluyser, OE Nieweg, E. van der Ploeg, K.G. Go, Willem Vaalburg
199429
13
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
British Journal of Cancer ·Daniel H. Palmer, Yuk Ting, Markus Peck‐Radosavljevic, Paul J. Ross, Janet Graham, Lætitia Fartoux, Andrzej Deptała, Matus Studeny, David Schnell, Julia Hocke, A-B. Loembé, Tim Meyer
201826
14
Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis
BMC Cancer ·K. Mross, Martin Büchert, Annette Frost, Michael Medinger, Peter Stopfer, Matus Studeny, R. Kaiser
201426
15
Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment
Clinical Colorectal Cancer ·Eric Van Cutsem, Takayuki Yoshino, Julia Hocke, Zohra Oum'Hamed, Matus Studeny, Josep Tabernero
201523
16
Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients.
Journal of Clinical Oncology ·Tim Eisen, Yaroslav Shparyk, Robert H. Jones, Nicholas MacLeod, Graham Temple, Helen Finnigan, R. Kaiser, Matus Studeny, Arsène Bienvenu Loembé, Igor Bondarenko
201321
17
A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer
European Journal of Cancer ·Eric Van Cutsem, Hans Prenen, Carmen Guillén‐Ponce, Jaafar Bennouna, Mélanie Di Benedetto, O. Bouché, Harry Staines, Zohra Oum'Hamed, Matus Studeny, Jaume Capdevila
201119
18
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas
Journal of Clinical Oncology ·Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki, Enriqueta Felip, Miguel F. Sanmamed, Olatunji B. Alese, Cyrus Sayehli, Edurne Arriola, Juergen Wolf, Liza C. Villaruz, Julia Bertulis, Matus Studeny, Mohamed Bouzaggou, Xiaoyan Fang, Daniel Morgensztern
20258
19
670P Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data
Annals of Oncology ·Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki, Eudald Felip, Miguel F. Sanmamed, Olatunji B. Alese, Cyrus Sayehli, E. Arriola Aperribay, Juergen Wolf, L. Villaruz, Matus Studeny, M. Bouzaggou, Xueliang Fang, Daniel Morgensztern
20247
20
Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC).
Journal of Clinical Oncology ·Daniel H. Palmer, Markus Peck‐Radosavljevic, Yuk Ting, Janet Graham, Lætitia Fartoux, Richard Hubner, Arsène Bienvenu Loembé, Matus Studeny, Julia Hocke, Tim Meyer
20136

About Matus Studeny

Matus Studeny is a scholar working on Oncology, Genetics, Radiology, Nuclear Medicine and Imaging, Cancer Research and Pulmonary and Respiratory Medicine, having authored 37 papers that have together received 3.0k indexed citations. Recurring topics across this work include Mesenchymal stem cell research (8 papers), CAR-T cell therapy research (6 papers), Colorectal Cancer Treatments and Studies (6 papers), Lung Cancer Research Studies (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Cancer Cells and Metastasis (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Genetics (1.5k citations), Oncology (1.2k citations), Cancer Research (401 citations), Biotechnology (172 citations) and Genetics (497 citations). Matus Studeny has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Michael Andreeff, Frank C. Marini, Claudia Zompetta, Jennifer L. Dembinski, Richard E. Champlin, Isaiah J. Fidler, F. Marini, B. Nebiyou Bekele, Richard Champlin and M. Andreeff. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, European Journal of Cancer and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erika L. SpaethBreakdown of academic impact, for papers by Joy GuminBreakdown of academic impact, for papers by G ParadisBreakdown of academic impact, for papers by Ross TuboBreakdown of academic impact, for papers by Ajeeta B. DashBreakdown of academic impact, for papers by Venkata Lokesh BattulaBreakdown of academic impact, for papers by Sandra A. RempelBreakdown of academic impact, for papers by Robert W. StormsBreakdown of academic impact, for papers by Kent ClaypoolBreakdown of academic impact, for papers by Laurie A. Milner